Sysmex Co. (OTCMKTS:SSMXY) Update on Short Interest

Sysmex Co. (OTCMKTS:SSMXY – Get Free Report ) was the target of a large increase in short interest in September. As of September 15th, there was short interest totaling 369,500 shares, an increase of 627.4% from August 31st’s total of 50,800 shares. Based on an average daily trading volume of 765,400 shares, the days-to-cover ratio is currently 0.5 days.

Sysmex stock performance

OTCMKTS:SSMXY traded down $0.37 during mid-day trading on Wednesday, hitting $19.16. The company’s stock had a trading volume of 27,799 shares, compared to its average volume of 116,646. Sysmex has a 12-month low of $14.38 and a 12-month high of $29.78. The company’s fifty day moving average price is $18.14 and its two hundred day moving average price is $17.19. The company has a current ratio of 3.23, a quick ratio of 2.40, and a debt-to-equity ratio of 0.11. The stock has a market cap of $12.06 billion, a P/E ratio of 37.82 and a beta of 0.84.

Sysmex (OTCMKTS:SSMXY – Get Your Free Report ) last posted its earnings results on Tuesday, August 6th. The company reported $0.11 earnings per share for the quarter. Sysmex had a return on equity of 11.15% and a net margin of 10.25%. The business had revenue of $718.13 million during the quarter. On average, equities analysts forecast that Sysmex will post 0.65 EPS for the current fiscal year.

About Sysmex

(Get a free report)

Sysmex Corporation is engaged in the development, manufacture and sale of diagnostic instruments, reagents and related software in Japan. Provides three- and five-part white blood cell differentiation tools for use in hematology; and transport systems for high-volume testing in laboratories. The company also offers automated urine particle analyzers; automatic blood coagulation analyzers; automated immunochemistry systems, which perform tests on minute amounts of sample, as well as reagents for testing infectious diseases and tumor markers; and flow cytometers to perform analyzes in the diagnosis of leukemia, malignant lymphoma and HIV/AIDS.

See Also

Get news and reviews for Sysmex Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sysmex and related companies with MarketBeat.com ‘s FREE daily email newsletter.